Crawford E David, Petrylak Daniel P, Shore Neal, Saad Fred, Slovin Susan F, Vogelzang Nicholas J, Keane Thomas E, Koo Phillip J, Gomella Leonard G, O'Sullivan Joe M, Tombal Bertrand, Concepcion Raoul S, Sieber Paul, Stone Nelson N, Finkelstein Steven E, Yu Evan Y
University of Colorado, Denver, CO.
Yale University, New Haven, CT.
Urology. 2017 Jun;104:150-159. doi: 10.1016/j.urology.2016.12.033. Epub 2017 Mar 14.
To offer recommendations on identification of disease progression, treatment management strategies, and suggestions on timing of initiating and discontinuing specific castration-resistant prostate cancer (CRPC) treatments.
The Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II Working Group convened to provide guidance on sequencing, combination, or layering of approved treatments for metastatic CRPC based on available data and clinical experience.
A consensus was developed to address important questions on management of patients with metastatic CRPC.
In the absence of large-scale clinical trials, the Working Group recommends that patients may best be managed with a layered approach of approved therapies with unique or complimentary mechanisms of action.
针对疾病进展的识别、治疗管理策略以及启动和停止特定去势抵抗性前列腺癌(CRPC)治疗的时机提供建议。
前列腺癌影像学评估用于检测晚期复发II工作组召开会议,根据现有数据和临床经验,就转移性CRPC的批准治疗的序贯、联合或分层提供指导。
就转移性CRPC患者管理的重要问题达成了共识。
在缺乏大规模临床试验的情况下,工作组建议采用具有独特或互补作用机制的批准疗法分层方法来管理患者,可能是最佳选择。